Genetics of hereditary cervical cancer

CME Journal of Gynecologic Oncology

Volumn 6, Issue 3, 2001, Pages 371-376

  Coinbra, H A ^a   Regateiro, F J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cervical carcinoma; Hereditary factors; HLA haplotypes; HPV; LKB1 gene; Metabolizing enzymes; MTHFR polymorphisms; P53 polymorphisms; Somatic genetic alterations

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HLA DQ ANTIGEN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CANCER GENETICS; CANCER MORTALITY; CANCER RISK; DISEASE ASSOCIATION; DNA POLYMORPHISM; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC RISK; HAPLOTYPE; HLA SYSTEM; HUMAN; ONCOGENE; ONCOGENE C ERB; ONCOGENE K RAS; ONCOGENE PIK3CA; REVIEW; SIGNAL TRANSDUCTION; SYNDROME; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 0035678390     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. The molecular basis and clinical aspects of Peutz-Jeghers syndrome
2. Dyskeratosis congenita: First report of its occurrence in female and review of the literature
3. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
4. Correlation of modified human-papillomavirus early-gene expression with altered growth properties in C4-1 cervical-carcinoma cells
5. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA
6. Interactions of HPV E6 and E7 oncoproteins with tumor suppressor gene products
7. Oncogenes and tumor angiogenesis: The HPV-16 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promotor in a p53 independent manner
8. Analysis of the physical states of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasia
9. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours
10. Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: Preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 ORFs
11. Mutational analysis of cis elements involved E2 modulation of human papillomavirus type 16 p97 and p105 promotors
12. Increased E6/E7 transcription in HPV 18 immortalized human keratinocytes results from inactivation of E2 and additional cellular events
13. Genetic analysis of in vitro progression of human papillomavirus-transfected human cervical cells
14. Induction of anchorage-independent growth of human embryonic fibroblasts with a deletion in the short arm of chromosome 11 by human papillomavirus type 16 DNA
15. Normal human chromosome 11 suppresses tumorigenicity of human cervical tumor cell line SiHa
16. Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells
17. Suppression in vivo of human-papillomavirus-type-18 E6-E7-gene expression in non-tumorigenic HeLa-fibroblast hybrid cells
18. Extinction of the HPV-18 upstream regulatory region in cervical-carcinoma cells after fusion with non-tumorigenic human keratinocytes under non-selective conditions
19. Expression of AP-1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells
20. Genetic complementation to non-tumorigenicity in cervical-carcinoma cells correlates with alterations in AP-1 composition
21. Conversion of HPV-18-positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-mediated repression of viral transcription and modification of the AP-1-transcription complex
22. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
23. Human papillomavirus genotype as a major determinant of the course of cervical cancer
24. Genetic characterization of the human papillomavirus (HPV) 18E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential
25. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype
26. High resolution analysis of chromosome 3p alterations in cervical carcinoma
27. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p
28. Allelotype analysis of cervical carcinoma
29. Genetic alterations at 5p15: A potential marker for progression of precancerous lesions of the uterine cervix
30. Loss of heterozygosity in cervical carcinoma; subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24
31. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix
32. Inactivation of tumor suppressor genes in uterine cervix carcinogenesis
33. Comparison of chromosome 3p deletions between cervical pre-cancers synchronous with and without invasive cancer
34. Loss of heterozigosity of the retinoblastoma and p53 genes in primary cervical carcinomas with human papillomavirus infection
35. Relationship between human papillomavirus infection and overexpression of p53 protein in cervical carcinomas and lymph node metastases
36. Relation between retinoblastoma and p53 proteins in human papilloma viruses 16/18 positive and negative cancers of the uterine cervix
37. Immunohistochemical prediction of radiation response and local control in radiation therapy for cervical cancer
38. Expression and mutational analysis of P53 in stage IB and IIA cervical cancers
39. Mutations in the TP53 gene and protein expression of p53, MDM2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load
40. bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma
41. Growth suppression of a cervical cancer cell line (TMCC-1) by the human wild-type p53 gene
42. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
43. Growth inhibition of human cervical cancer cells with the recombinant adenovirus p53 in vitro
44. Biallelic inactivating mutations and an occult germline mutation of PTEN in primary cervical carcinomas
45. PIK3CA as an oncogene in cervical cancer
46. Differences in K-ras codon 12 mutation frequency between "high-risk" and "low-risk" HPV-infected samples
47. Association between activated K-ras and c-erbB-2 oncogene with "high-risk" and "low-risk", human papilloma virus types in preinvasive cervical lesions
48. Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma
49. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
50. Correlation between EGFR and c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in cervical carcinoma
51. Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy
52. Frequent amplification of c-erbB-2 (HER-2/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections
53. Proto-oncogenes and p53 protein expression in normal cervical stratified squamous epithelium and cervical intra-epithelial neoplasia
54. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer
55. The presence of human papillomavirus-16/-18 E6, p53, and bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer
56. Prognostic significance of Bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix
57. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer
58. Microsatellite instability in cervical and endometrial carcinoma
59. Familial risks in cervical cancer: Is there a hereditary component?
60. Genetic link to cervical tumours
61. Cervical cancer risk: Is there a genetic component?
62. Cancer in twins: Genetic and non-genetic familial risk factors
63. Linkage to nasopharyngeal carcinoma susceptibility locus to HLA region
64. Loss of MHC class I expression in cervical carcinomas
65. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class 1 human leukocyte antigens by steroid hormones in cervical tumor cells
66. Linkage of regression and malignant conversion of papillomas to MHC class II genes
67. HLA-DQB17*03 and cervical intraepithelial neoplasia type III
68. HLA and cervical carcinoma
69. DQA1 and DQB1 genes in patients with squamous-cell carcinoma of the cervix: Relationship to human papillomavirus infection and prognosis
70. High risk for squamous cell carcinoma of the cervix for women with HLA-DQw3
71. Association of human leukocyte antigen-B1*03 with cervical cancer in Japanese women aged 35 years and younger
72. Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602, *301, *0303 alleles
73. Association between HLA-DQB1 alleles and risk for cervical cancer in African-American women
74. HLA antigens and cervical carcinoma
75. Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer
76. HLA-DQB1*03 and cervical intraepithelial neoplasia grades I-III
77. Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women
78. Comparison of HLA DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma
79. HLA DR-DQ associations with cervical carcinoma show papillomavirus type specificity
80. HPV 16 infection and progression of cervical intra-epithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants
81. MICA gene polymorphism and the risk to develop cervical intraepithelial neoplasia
82. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
83. P53 polymorphism and risk of cervical cancer
84. P53 polymorphism and risk of cervical cancer
85. P53 polymorphism and risk of cervical cancer
86. P53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy
87. Integration of virus DNA and p53 codon 72 polymorphism in human pappilomavirus type 16 positive cervical cancers
88. Methylenetetrahydrofolate reductase (MTHFR) polymorphism increases the risk of cervical intraepithelial neoplasia
89. Glutathione S-transferase M1 genotypes and the risk of squamous carcinoma of the cervix: A population-based case-control study
90. Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1 and CYP2E1: Relation to the incidence rate of cervical carcinoma
91. Progression of cervical intraepithelial neoplasia to cervical cancer: Interactions of cytochrome P450 CYP2D6 EM and glutathione S-transferase GSTM1 null genotypes and cigarette smoking
92. HLA DR-DQ haplotype and susceptibility to cervical carcinoma: Indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18